Dasatinib regimens for patients with chronic myeloid leukemia

Nature Reviews Clinical Oncology

Volumn 6, Issue 12, 2009, Pages 680-682

  Guilhot, François ^a   Roy, Lydia ^a  

^a POITIERS UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DASATINIB; DIURETIC AGENT; IMATINIB; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR; STEROID; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE; THIAZOLE DERIVATIVE;

ADVANCED CANCER; BONE MARROW SUPPRESSION; CANCER GROWTH; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CYTOGENETICS; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG PULSE THERAPY; DRUG SAFETY; DRUG TOLERABILITY; FLUID RETENTION; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEMATOLOGIC DISEASE; HUMAN; LEUKEMIA RELAPSE; OVERALL SURVIVAL; PLEURA EFFUSION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RISK FACTOR; SHORT SURVEY; SIDE EFFECT; TREATMENT DURATION; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; DRUG ANTAGONISM; NOTE;

HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PROGNOSIS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; THIAZOLES;

EID: 75649118246     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2009.160     Document Type: Short Survey

References (9)

1. Talpaz, M. et al. Imatinib induces durable hematologic and cytogenetic responses In patients with accelerated phase: results of a phase 2 study. Blood 99, 1928-1937 (2002).
2. Talpaz, M. et al. Dasatlnib in imatinibresistant Philadelphia chromosome-positive leukemia. N. Engl. J. Med. 354, 2531-2541 (2006).
3. Kantarjian, H. et al. Phase 3 study of dasatinib 140 mg once daily versus twice daily in patients with chronic myeloid leukemia In accelerated phase resistant or intolerant to imatinib: 15 months median follow-up. Blood 113, 6322-6329 (2009).
4. Guilhot, F. et al. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or-intolerant chronic myeloid leukemia in accelerated phase. Blood 109, 4143-4150 (2007). (Pubitemid 46743375)
5. Hochhaus, A. et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic phase chronic myeloid leukemia after failure of imatinib therapy. Blood 109, 2303-2309 (2006). (Pubitemid 46425867)
6. Cortes, J. et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or-intolerant chronic myeloid leukemia In blast crisis. Blood 109, 3207-3213 (2006).
7. Alfonso Quintás-Cardama, A. et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J. Clin. Oncol. 25, 3908-3914 (2007).
8. Le Coutre, P et al. Nilotinib (formerly AMN 107), a highly selective BCR-ABL tyrosine kinase inhibitor, is a active in patients with imatinibresistant or-intolerant accelerated-phase chronic myelogenous leukemia. Blood 111, 1834-1839 (2008).
9. Shah, N. P et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improved tolerability in imatinibresistant and -intolerant chronic-phase chronic myeloid leukemia. J. Clin. Oncol. 26, 3204-3212 (2008).